ArticleFrontiers in immunology2024

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.

Wanying Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.